Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 33.21
ARWR's Cash to Debt is ranked higher than
72% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. ARWR: 33.21 )
ARWR' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 33.21

Equity to Asset 0.89
ARWR's Equity to Asset is ranked higher than
91% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ARWR: 0.89 )
ARWR' s 10-Year Equity to Asset Range
Min: -39.56   Max: 0.93
Current: 0.89

-39.56
0.93
F-Score: 3
Z-Score: 32.71
M-Score: -3.95
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -8478.97
ARWR's Operating margin (%) is ranked lower than
51% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. ARWR: -8478.97 )
ARWR' s 10-Year Operating margin (%) Range
Min: -70800   Max: -40
Current: -8478.97

-70800
-40
Net-margin (%) -10738.97
ARWR's Net-margin (%) is ranked lower than
52% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. ARWR: -10738.97 )
ARWR' s 10-Year Net-margin (%) Range
Min: -14371.43   Max: 1602.7
Current: -10738.97

-14371.43
1602.7
ROE (%) -113.25
ARWR's ROE (%) is ranked higher than
54% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. ARWR: -113.25 )
ARWR' s 10-Year ROE (%) Range
Min: -397.45   Max: -6.69
Current: -113.25

-397.45
-6.69
ROA (%) -83.43
ARWR's ROA (%) is ranked higher than
53% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. ARWR: -83.43 )
ARWR' s 10-Year ROA (%) Range
Min: -791.67   Max: 723.17
Current: -83.43

-791.67
723.17
ROC (Joel Greenblatt) (%) -699.94
ARWR's ROC (Joel Greenblatt) (%) is ranked higher than
64% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. ARWR: -699.94 )
ARWR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -39320   Max: -37.5
Current: -699.94

-39320
-37.5
EBITDA Growth (%) 3.40
ARWR's EBITDA Growth (%) is ranked higher than
84% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. ARWR: 3.40 )
ARWR' s 10-Year EBITDA Growth (%) Range
Min: -56.3   Max: 190.5
Current: 3.4

-56.3
190.5
EPS Growth (%) 38.40
ARWR's EPS Growth (%) is ranked higher than
96% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. ARWR: 38.40 )
ARWR' s 10-Year EPS Growth (%) Range
Min: -75.1   Max: 162.1
Current: 38.4

-75.1
162.1
» ARWR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

ARWR Guru Trades in

ARWR Guru Trades in

ARWR Guru Trades in

Q4 2013

ARWR Guru Trades in Q4 2013

Steven Cohen 1,500,000 sh (New)
Jim Simons 54,400 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with ARWR



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.40
ARWR's P/B is ranked higher than
53% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. ARWR: 5.40 )
ARWR' s 10-Year P/B Range
Min: 1.43   Max: 75.56
Current: 5.4

1.43
75.56
P/S 2000.00
ARWR's P/S is ranked lower than
95% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. ARWR: 2000.00 )
ARWR' s 10-Year P/S Range
Min: 0   Max: 2500
Current: 2000

0
2500
EV-to-EBIT 11.40
ARWR's EV-to-EBIT is ranked higher than
77% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. ARWR: 11.40 )
ARWR' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 11.4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.70
ARWR's Price/Net Cash is ranked higher than
66% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. ARWR: 6.70 )
ARWR' s 10-Year Price/Net Cash Range
Min: 0.05   Max: 103.64
Current: 6.7

0.05
103.64
Price/Net Current Asset Value 6.70
ARWR's Price/Net Current Asset Value is ranked higher than
64% of the 525 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. ARWR: 6.70 )
ARWR' s 10-Year Price/Net Current Asset Value Range
Min: 0.05   Max: 87.69
Current: 6.7

0.05
87.69
Price/Tangible Book 5.60
ARWR's Price/Tangible Book is ranked higher than
57% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. ARWR: 5.60 )
ARWR' s 10-Year Price/Tangible Book Range
Min: 0.04   Max: 54.5
Current: 5.6

0.04
54.5
Price/Median PS Value 13.80
ARWR's Price/Median PS Value is ranked lower than
81% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ARWR: 13.80 )
ARWR' s 10-Year Price/Median PS Value Range
Min: 0.04   Max: 28.81
Current: 13.8

0.04
28.81
Forward Rate of Return (Yacktman) -38.49
ARWR's Forward Rate of Return (Yacktman) is ranked higher than
64% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. ARWR: -38.49 )
ARWR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -60   Max: -7.5
Current: -38.49

-60
-7.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:HDP1.Germany
Arrowhead Research Corp. was originally incorporated in South Dakota in 1989, and was reincorporated in Delaware in 2000. It is a development stage nanotechnology holding company that forms, acquires, and operates subsidiaries commercializing innovative nanotechnologies. By working closely with scientists and universities, Arrowhead identifies advances in nanotechnology and matches them with product development opportunities in high-growth markets. The Company is focusing on developing and advancing a portfolio of subsidiaries in the field of nanomedicine. Arrowhead owns two majority-owned operating subsidiaries, Calando Pharmaceuticals and Unidym, Inc. and has minority investments in two early-stage nanotechnology companies, Nanotope, Inc. and Leonardo Biosystems, Inc. Arrowhead also owns two nonoperating subsidiaries, Agonn Systems, Inc. and Tego Biosciences Corporation. Arrowhead's strategy is to maintain or build a majority ownership position in each portfolio company, thus providing significant exposure to their growth. Arrowhead's ultimate goal is to monetize the value of its subsidiaries through an initial public offering of subsidiary stock or a sale of a subsidiary to another company.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

Truthtracer@twitter
ReplyTruthtracer@twitter - 3 months ago
Correction, carefully read the scientific foundation shared in the 4th quarter report.
Truthtracer@twitter
ReplyTruthtracer@twitter - 3 months ago
Pay attention to the science in the third quarter report. Institutional holdings have increased from 30% to over 70% in 3 months. Reputable, longer term holders...

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide